October 26th 2012
For those who treat overweight or obese cancer patients, choosing doses of chemotherapy can be a sweat-producing endeavor.
October 19th 2012
Many researchers and oncologists anticipate a role for antiangiogenic strategies in future treatment paradigms; yet just what that role will be remains elusive.
October 15th 2012
The promise of a solution somewhere on the horizon for America's drug shortages isn't enough for the registered nurse who navigates shortages every day.
Within the past two years, the oncology community has seen the FDA approve three practice-changing therapies for breast cancer and the progress of a promising fourth agent, T-DM1.
October 5th 2012
During the 11th International Congress on The Future of Breast Cancer, Hope Rugo, MD, offered a snapshot of the research community's progress in the study and treatment of the disease.
September 4th 2012
Anemia is common and associated with functional disability in patients with cancer aged ≥65 years, according to the results of a study presented at ASCO 2012.
Patients with cancer who have lower incomes are less likely to participate in clinical trials, according to a large national survey.
August 29th 2012
Fresh strategies for grappling with the chronic, and at times critical, shortages of cancer drugs that have frustrated the oncology community for the past decade are likely to help alleviate supply problems.
August 28th 2012
Two medications that are not recommended in guidelines for the standard treatment of cancer-related febrile neutropenia are commonly used- particularly outside of high-volume medical settings- yet are not effective.
August 16th 2012
The novel drug enzalutamide (formerly MDV3100) significantly improved overall survival in men with metastatic castrate-resistant prostate cancer (mCRPC).
August 6th 2012
Among patients with early-stage cervical cancer, women aged greater than 65 years are less likely than younger women to be treated with surgery as compared with chemoradiation.
Men with a baseline PSA between 1.5 and 4.0 ng/mL faced a 15-fold increase in prostate cancer over a four-year period as compared with men whose baseline PSA levels were
August 1st 2012
Since the phase III AFFIRM trial of enzalutamide was halted after meeting its endpoint of improved OS, physicians have remained hopeful about its potential as a treatment for prostate cancer.
June 28th 2012
Leaders in the oncology care and research communities largely applauded the US Supreme Court ruling Thursday that upholds the Affordable Care Act.
June 25th 2012
Enzalutamide seems poised to become an exciting addition to the growing list of novel therapies approved for the treatment of prostate cancer.
June 15th 2012
An interview with David Cella, PhD, the developer of the FACIT system of questionnaires that scientifically measure the quality of life of patients being treated for cancer.
June 12th 2012
Checking in with patients can bring positive results, since oncology nurses are able to offer interventions for most symptoms of cancer treatment. Includes an in-depth look at telephone triage.
Three case studies focused on how best to sequence therapy in prostate cancer were presented by Daniel P. Petrylak, MD, and discussed by a panel that included Robert Dreicer, MD, and Oliver Sartor, MD.
June 5th 2012
Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.
Drug manufacturers are working with the FDA to report anticipated shortages earlier and ensure alternative sources of needed drugs are available.